Heron Therapeutics, Inc. (NASDAQ:HRTX) has received an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $31.63.

A number of research firms have recently commented on HRTX. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, August 18th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Finally, Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Heron Therapeutics, Inc. (HRTX) Target Price at $31.63” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://theolympiareport.com/2017/08/27/brokerages-set-heron-therapeutics-inc-hrtx-target-price-at-31-63.html.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down 0.91% on Tuesday, hitting $16.40. The company had a trading volume of 331,598 shares. The firm has a 50-day moving average price of $15.77 and a 200 day moving average price of $14.76. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. Analysts forecast that Heron Therapeutics will post ($3.51) EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of HRTX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Heron Therapeutics during the first quarter valued at about $1,035,000. Virginia Retirement Systems ET AL acquired a new stake in Heron Therapeutics during the first quarter valued at about $459,000. Parametric Portfolio Associates LLC raised its stake in Heron Therapeutics by 86.8% in the first quarter. Parametric Portfolio Associates LLC now owns 33,139 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 15,394 shares in the last quarter. Swiss National Bank raised its stake in Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock valued at $1,089,000 after buying an additional 20,700 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock valued at $2,861,000 after buying an additional 40,657 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.